COCP Cocrystal Pharma, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1412486 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-17.2%
TTM EPS YoY18.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-219.1%
ROA-131.6%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets60.5%
Debt / equity0.00x
Current ratio1.72x
Interest coverage122.45x
Cash quality & payout
Operating cash flow / net income0.78x
Accruals ratio-28.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $5.05M | $12.54M |
| SG&A expense | $3.96M | $5.34M |
| Operating income | -$9.02M | -$17.88M |
| Interest expense | -$134,000 | -$537,000 |
| Pretax income | -$8.83M | -$18.63M |
| Net income | -$8.83M | -$17.50M |
| EBITDA | -$8.95M | -$17.75M |
| EPS (basic) | -0.78 | -1.72 |
| EPS (diluted) | -0.78 | -1.72 |
| Weighted avg. shares (diluted) | 11.29M | 10.17M |
| Balance sheet | ||
| Cash & equivalents | $7.03M | $9.86M |
| Current assets | $8.13M | $11.58M |
| PP&E, net | $93,000 | $153,000 |
| Total assets | $9.71M | $13.46M |
| Current liabilities | $2.21M | $2.43M |
| Total liabilities | $3.38M | $3.93M |
| Shareholders' equity | $6.33M | $9.52M |
| Shares outstanding | 13.78M | 10.17M |
| Cash flow statement | ||
| Operating cash flow | -$8.19M | -$16.48M |
| Capital expenditure | $12,000 | $8,000 |
| Free cash flow | -$8.20M | -$16.49M |
| Investing cash flow | -$12,000 | -$8,000 |
| Financing cash flow | $5.37M | — |
| Depreciation & amortization | $72,000 | $126,000 |
| Stock-based compensation | $270,000 | $643,000 |
Free plan shows the latest 2 periods; Pro shows all 16 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.